AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 04:02:10 2026-04-21 pm EDT			5-day change	1st Jan Change
205.12 ^USD	+0.69%		-0.65%	-10.23%

Apr. 21	Correction to AbbVie Article on April 20	DJ
Apr. 21	Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target	MT

Transcript : AbbVie Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11

Published on 03/03/2026 at 12:50 pm EST - Modified on 03/04/2026 at 01:50 am EST

S&P Capital IQ

Presenter Speech
Steve Scala (Analysts)

So good morning once again, and welcome to TD Cowen's 46th Annual Healthcare Conference. We're absolutely delighted to have AbbVie back with us again this year.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about AbbVie Inc.

Apr. 21	Correction to AbbVie Article on April 20	DJ
Apr. 21	Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target	MT
Apr. 20	AbbVie Sponsors New BioLabs Facility in Toronto	DJ
Apr. 20	AbbVie and Biolabs team up to support Life Sciences Innovation in Canada	RE
Apr. 20	Amazon's collusion drove up consumer prices, California says, citing new evidence	RE
Apr. 20	Ruled by Headlines
Apr. 20	Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie	CI
Apr. 20	Nxera Pharma to Receive $10 Million Milestone from AbbVie for Neurology Collaboration	MT
Apr. 20	AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration	MT
Apr. 20	Nxera Pharma Co Ltd - to receive US$10 million milestone payment from AbbVie under collaboration targeting neurological diseases	RE
Apr. 16	Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026	CI
Apr. 15	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
Apr. 15	RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement	MT
Apr. 15	RemeGen Co., Ltd. and Abbvie Enter Exclusive License Agreement for RC148 with USD 650 Million Upfront Payment	CI
Apr. 13	Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating	MT